Montanova Capital LLC Has $6.87 Million Stake in DexCom, Inc. $DXCM

Montanova Capital LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 221.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,980 shares of the medical device company’s stock after purchasing an additional 70,300 shares during the period. Montanova Capital LLC’s holdings in DexCom were worth $6,868,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of DXCM. Brighton Jones LLC grew its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC boosted its stake in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Empowered Funds LLC increased its holdings in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth raised its stake in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $91.06 on Tuesday. The firm has a market cap of $34.36 billion, a PE ratio of 35.99, a PEG ratio of 1.53 and a beta of 1.41. The stock’s fifty day moving average price is $79.64 and its two-hundred day moving average price is $71.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the prior year, the company earned $0.48 EPS. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, equities research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 2,565 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the sale, the executive vice president owned 126,043 shares of the company’s stock, valued at $11,138,419.91. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 75,600 shares of company stock valued at $5,673,342. Insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on DXCM. Royal Bank Of Canada raised their price objective on DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. UBS Group set a $96.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Tuesday, July 28th. Wall Street Zen lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. Benchmark boosted their price target on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $94.00 price objective on shares of DexCom in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.